Print

Clinilabs, Inc. Release: Dr. Gary Zammit to Present on GCP Compliance for Phase I Studies  
10/31/2011 2:10:47 PM

New York, NY (October 31, 2011) – Clinilabs, a full-service contract research organization that provides early-phase and specialty clinical drug development services to industry, announced today that President and CEO, Dr. Gary Zammit, will present at the New England Regional Chapter Society of Quality Assurance (NERCSQA) Good Clinical Practices (GCP) training in Framingham, MA.

The two-day workshop brings together expert leaders in the pharmaceutical industry to discuss recent developments and trends in GCP compliance and clinical research. The topics range from an introduction on GCPs to how to manage the challenges in delivering quality clinical data. Dr. Zammit, an expert in human subject protection compliance during pharmaceutical development, will discuss GCP compliance for Phase I studies. Dr. Zammit, states: “It’s both a pleasure and a privilege to take part in this forum. This workshop promises to be informative and interactive, and will address key developments and challenges in GCPs. It’s important to keep abreast of GCP issues in order to maintain the integrity of data used to support new drug applications.” The two-day workshop will be held on November 7-8 at the Sheraton Hotel and Conference Center.

About NERCSQA

NERCSQA is committed to providing local, high quality, affordable training on current GCP topics with seminars three times a year. Experienced QA professionals in the environmental, pharmaceutical and biotechnology fields of government, private industry, research, and academia present training sessions in a variety of formats, from roundtable discussions to interactive workshops. For more information, please visit http://www.nercsqa.org.

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. Clinilabs is recognized globally as a leading specialty CRO, and has made important contributions to eleven successful new drug applications (NDAs) since 2001. For more information, please visit www.clinilabs.com.

For more information or to schedule an interview, please contact Hannah D’Aoust at 646.215.6480 or e-mail hdaoust@clinilabs.com


//-->